000119849 001__ 119849
000119849 005__ 20240228134956.0
000119849 0247_ $$2doi$$a10.1111/jth.12715
000119849 0247_ $$2pmid$$apmid:25163932
000119849 0247_ $$2ISSN$$a1538-7836
000119849 0247_ $$2ISSN$$a1538-7933
000119849 037__ $$aDKFZ-2017-00444
000119849 041__ $$aeng
000119849 082__ $$a610
000119849 1001_ $$aD'Asti, E.$$b0
000119849 245__ $$aCoagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk.312
000119849 260__ $$aOxford$$bWiley-Blackwell$$c2014
000119849 3367_ $$2DRIVER$$aarticle
000119849 3367_ $$2DataCite$$aOutput Types/Journal article
000119849 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1490172999_2260
000119849 3367_ $$2BibTeX$$aARTICLE
000119849 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119849 3367_ $$00$$2EndNote$$aJournal Article
000119849 520__ $$aThe coagulation system becomes activated during progression and therapy of high-grade brain tumors. Triggering tissue factor (F3/TF) and thrombin receptors (F2R/PAR-1) may influence the vascular tumor microenvironment and angiogenesis irrespective of clinically apparent thrombosis. These processes are poorly understood in medulloblastoma (MB), in which diverse oncogenic pathways define at least four molecular disease subtypes (WNT, SHH, Group 3 and Group 4). We asked whether there is a link between molecular subtype and the network of vascular regulators expressed in MB.Using R2 microarray analysis and visualization platform, we mined MB datasets for differential expression of vascular (coagulation and angiogenesis)-related genes, and explored their link to known oncogenic drivers. We evaluated the functional significance of this link in DAOY cells in vitro following growth factor and thrombin stimulation.The coagulome and angiome differ across MB subtypes. F3/TF and F2R/PAR-1 mRNA expression are upregulated in SHH tumors and correlate with higher levels of hepatocyte growth factor receptor (MET). Cultured DAOY (MB) cells exhibit an up-regulation of F3/TF and F2R/PAR-1 following combined SHH and MET ligand (HGF) treatment. These factors cooperate with thrombin, impacting the profile of vascular regulators, including interleukin 1β (IL1B) and chondromodulin 1 (LECT1).Coagulation pathway sensors (F3/TF, F2R/PAR-1) are expressed in MB in a subtype-specific manner, and may be functionally linked to SHH and MET circuitry. Thus coagulation system perturbations may elicit subtype/context-specific changes in vascular and cellular responses in MB.
000119849 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000119849 588__ $$aDataset connected to CrossRef, PubMed,
000119849 650_7 $$2NLM Chemicals$$aAngiogenic Proteins
000119849 650_7 $$2NLM Chemicals$$aHedgehog Proteins
000119849 650_7 $$2NLM Chemicals$$aIntercellular Signaling Peptides and Proteins
000119849 650_7 $$2NLM Chemicals$$aRNA, Messenger
000119849 650_7 $$2NLM Chemicals$$aReceptor, PAR-1
000119849 650_7 $$067256-21-7$$2NLM Chemicals$$aHepatocyte Growth Factor
000119849 650_7 $$09035-58-9$$2NLM Chemicals$$aThromboplastin
000119849 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aMET protein, human
000119849 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aProto-Oncogene Proteins c-met
000119849 650_7 $$0EC 3.4.21.5$$2NLM Chemicals$$aThrombin
000119849 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b1$$udkfz
000119849 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b2$$udkfz
000119849 7001_ $$aRak, J.$$b3
000119849 773__ $$0PERI:(DE-600)2099291-9$$a10.1111/jth.12715$$gVol. 12, no. 11, p. 1838 - 1849$$n11$$p1838 - 1849$$tJournal of thrombosis and haemostasis$$v12$$x1538-7933$$y2014
000119849 909CO $$ooai:inrepo02.dkfz.de:119849$$pVDB
000119849 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119849 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119849 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000119849 9141_ $$y2014
000119849 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ THROMB HAEMOST : 2015
000119849 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119849 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119849 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119849 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119849 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119849 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119849 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119849 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119849 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119849 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119849 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ THROMB HAEMOST : 2015
000119849 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000119849 980__ $$ajournal
000119849 980__ $$aVDB
000119849 980__ $$aI:(DE-He78)B062-20160331
000119849 980__ $$aUNRESTRICTED